Tags

Type your tag names separated by a space and hit enter

The effects of parity, oral contraceptive use and hormone replacement therapy on the incidence of varicose veins.
J Obstet Gynaecol. 2006 Jul; 26(5):448-51.JO

Abstract

Three population-based age cohorts (40-, 50- and 60-years old) of women (n = 3,590) were followed up to find out if pregnancies, use of oral contraceptives (OCs) or hormone replacement therapy (HRT) affect the appearance of varicose veins. Results were presented as odds ratios (OR) of prevalences at entry (POR) and as incidence odds ratios (IOR) during the 5-year follow-up. Parity with three or more births was an independent risk factor for varicose veins IOR 2.0 (95% confidence interval (CI), 1.0 - 3.9). OC use showed a small and not significant protective effect for varicose veins, both POR and IOR equal to 0.9. HRT use indicated an increased risk of varicose veins, with POR 1.3 (1.0 - 1.7), but in the follow-up, the effect disappeared, IOR 1.0 (0.5 - 1.9). As a conclusion, higher age and high parity are characteristic for varicose veins. The use of HRT or OCs do not increase the risk.

Authors+Show Affiliations

Tampere School of Public Health, Tampere University, Finland. jari.laurikka@pshp.fiNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

16846875

Citation

Jukkola, T M., et al. "The Effects of Parity, Oral Contraceptive Use and Hormone Replacement Therapy On the Incidence of Varicose Veins." Journal of Obstetrics and Gynaecology : the Journal of the Institute of Obstetrics and Gynaecology, vol. 26, no. 5, 2006, pp. 448-51.
Jukkola TM, Mäkivaara LA, Luukkaala T, et al. The effects of parity, oral contraceptive use and hormone replacement therapy on the incidence of varicose veins. J Obstet Gynaecol. 2006;26(5):448-51.
Jukkola, T. M., Mäkivaara, L. A., Luukkaala, T., Hakama, M., & Laurikka, J. (2006). The effects of parity, oral contraceptive use and hormone replacement therapy on the incidence of varicose veins. Journal of Obstetrics and Gynaecology : the Journal of the Institute of Obstetrics and Gynaecology, 26(5), 448-51.
Jukkola TM, et al. The Effects of Parity, Oral Contraceptive Use and Hormone Replacement Therapy On the Incidence of Varicose Veins. J Obstet Gynaecol. 2006;26(5):448-51. PubMed PMID: 16846875.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The effects of parity, oral contraceptive use and hormone replacement therapy on the incidence of varicose veins. AU - Jukkola,T M, AU - Mäkivaara,L A, AU - Luukkaala,T, AU - Hakama,M, AU - Laurikka,J, PY - 2006/7/19/pubmed PY - 2006/10/27/medline PY - 2006/7/19/entrez SP - 448 EP - 51 JF - Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology JO - J Obstet Gynaecol VL - 26 IS - 5 N2 - Three population-based age cohorts (40-, 50- and 60-years old) of women (n = 3,590) were followed up to find out if pregnancies, use of oral contraceptives (OCs) or hormone replacement therapy (HRT) affect the appearance of varicose veins. Results were presented as odds ratios (OR) of prevalences at entry (POR) and as incidence odds ratios (IOR) during the 5-year follow-up. Parity with three or more births was an independent risk factor for varicose veins IOR 2.0 (95% confidence interval (CI), 1.0 - 3.9). OC use showed a small and not significant protective effect for varicose veins, both POR and IOR equal to 0.9. HRT use indicated an increased risk of varicose veins, with POR 1.3 (1.0 - 1.7), but in the follow-up, the effect disappeared, IOR 1.0 (0.5 - 1.9). As a conclusion, higher age and high parity are characteristic for varicose veins. The use of HRT or OCs do not increase the risk. SN - 0144-3615 UR - https://www.unboundmedicine.com/medline/citation/16846875/The_effects_of_parity_oral_contraceptive_use_and_hormone_replacement_therapy_on_the_incidence_of_varicose_veins_ L2 - https://www.tandfonline.com/doi/full/10.1080/01443610600747389 DB - PRIME DP - Unbound Medicine ER -